drugset / Trial / NCT00273884

Amonafide in Combination With Cytarabine in Secondary AML

NCT00273884

Phase 2 Completed 80 enrolled Xanthus Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.

Timeline

Start
2005-08
Primary completion
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Amonafide Small molecule
Background Cytarabine Small molecule